The Role of Pharmaceutical Quality Control in Preventing Public Health Risks in United States

Abstract

This study examined the role of pharmaceutical quality control systems in preventing public health risks in the United States through a comprehensive quantitative analysis of manufacturing and regulatory data. The dataset comprised 150 FDA-registered pharmaceutical manufacturing facilities, 12,500 batch production records, and 2,300 inspection reports collected over a five-year period. The analysis evaluated the relationship between quality control compliance and key public health risk indicators, including product recalls, adverse drug events, and regulatory warning letters. The findings revealed a statistically significant inverse relationship between quality control rigor and risk outcomes, with facilities implementing advanced quality systems demonstrating a 42% reduction in product recall rates and a 37% decrease in FDA warning letters compared to those using conventional methods. Additionally, adverse drug event rates were reduced from 6.2 to 3.8 per 1,000 batches in high-compliance facilities, indicating substantial improvements in patient safety outcomes. Regression analysis further confirmed that each unit increase in compliance score was associated with a 0.28 decrease in recall probability, while high-compliance facilities were 2.8 times less likely to experience critical quality failures (OR = 0.36, 95% CI: 0.28–0.46, p < 0.001). Sub-group analysis indicated that sterile injectable manufacturers achieved the highest reduction in contamination-related recalls (55%), whereas oral solid dosage manufacturers showed a moderate reduction of 29%. Large-scale facilities exhibited lower defect rates (2.3%) compared to smaller facilities (4.9%), and facilities adopting AI-driven quality control systems demonstrated near-zero defect rates (0.8%). Temporal analysis further showed that increased adoption of advanced quality systems from 52% to 82% over five years corresponded with a decline in recall rates from 6.8% to 3.6%. Overall, the study demonstrated that robust pharmaceutical quality control systems significantly reduced public health risks and enhanced manufacturing reliability. These findings underscored the importance of regulatory enforcement, technological integration, and continuous quality monitoring in ensuring patient safety and strengthening pharmaceutical governance.